"We have a solid platform for long-term sustainable growth"

rojoniwazifa53

AstraZeneca has once again presented growth data for the third consecutive quarter for the 3 months ended September 30, compared to the same period of the previous year. The pharmaceutical company has earned 50% more than in the third quarter of 2020, after billing 9,866 million dollars (8,604 million euros at the current exchange rate) compared to 6,578 million (5,737 million euros) in the same period of the previous year. Without taking into account the sales of the vaccine that it has developed together with the University of Oxford against COVID-19, total income – worth 8,816 million dollars (7,688 million euros) – has increased by 34% compared to 2020.

AstraZeneca's scientific leadership continues to deliver strong revenue growth and exceptional pipeline delivery, with 8 positive late-stage results for 7 drugs since June, including the antibody combination for the prevention and treatment  Malaysia WhatsApp Number List of COVID-19," AstraZeneca CEO Pascal Soriot celebrates in the statement. So far this year, the pharmaceutical company has invoiced 25,406 million dollars (22,158 million euros). Compared to  the 19,207 million dollars (16,751 million euros) of the first 9 months of 2020, the figure is 32% higher. Pfizer reinforces its leadership: 4 factors that explain why Moderna has lost potential in the messenger RNA vaccine business Analysts' forecasts for AstraZeneca were around $9.52 billion (more than €8.3 billion), as Business Insider had previously reported.



Therefore, also for the third consecutive quarter, AstraZeneca has exceeded analysts' expectations . "Our broad portfolio of medicines and our diversified geographic exposure provide a solid platform for long-term sustainable growth ," AstraZeneca CEO Pascal Soriot defends in the statement. These last 3 months, vaccine sales have generated income of more than 1,000 million dollars (872 million euros) — 12% more than in the second quarter of the year, when it had a turnover of 894 million dollars (757 million euros). euros)—. And oncology drugs (19%), CVRM1 (14%) and R&I2 (16%) have also achieved double-digit growth in revenue, according to the report. AstraZeneca maintains its revenue forecasts for 2021 despite reporting losses of more than $2 billion.